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Abstract
PEGylated proteins are widely used for therapeutic applications, therefore a fundamental 
understanding of the conjugates’ structure and their behaviour in solution is essential to promote 
new developments in this field. In the present work, myoglobin-poly(ethylene glycol) conjugates 
were synthesized and studied by using differential scanning calorimetry and UV-visible 
spectroscopy to obtain information on the bioconjugates’ thermodynamic stability, also focusing on 
the PEG’s role on the solvent-protein surface interaction. The overall results of this study indicated 
a thermal destabilization of the proteins that follows the extent of the bioconjugation without, 
however, compromising the native structure which remains functional. Moreover, the myoglobin 
PEGylation prevented the post-denaturation aggregation phenomena and enhanced the protein 
thermal reversibility. The thermodynamic interpretation of the data indicated that the 
bioconjugation influences the solvent-exposed protein surface difference between native and 
denatured state, contributing to the interpretation of the overall protein modification and 
functionality.
Keywords: PEGylation, calorimetry, protein unfolding, unfolding reversibility, protein-
polymer conjugation.
1. Introduction
The biotechnology evolution of the last century has underlined the great potentialities of protein 
and peptides as therapeutic agents. Nowadays more than 90 protein based compound are 
industrially produced and used as potent drugs for the treatment of severe diseases [1,2]. Despite 
their usefulness, they often exhibit several drawbacks, among which there are short shelf-life, low 
solubility in water and short life time inside the body [3]. Several strategies have been developed to 
avoid or decrease these limits, reducing the production costs of the drugs and their dosing frequency 
for patients [4]. One of the most promising strategies is bioconjugation, that consists in the covalent 
attachment of synthetic polymers to the proteins in order to form protein-polymer conjugates [5].
Poly(ethylene glycol) (PEG) is the most common polymer in bioconjugation [6]. Today there are 13 
PEG-protein conjugates approved from U.S. Food and Drug Administration and used for 
therapeutic purposes, while many others are currently under clinical trials [7–10]. The conjugates 
can perform several functions: replacement therapies for native enzyme deficiencies (Adagen®, 
Oncaspar®, Krystexxa®), stimulation of immune responses (PEG-Intron®, PEGASYS®, 
Plegridy®), regulation of blood cells production (Mircera®, Omontys®, Adinovate®), stimulation 
or inhibition in the production of important regulation substances (Neulasta®, Somavert®, 
Macugen®) and can be used against several diseases. The covalent bond of the polymer induces the 
formation of a protective shield around the protein-based drug, resulting often in an improvement of 
some properties, as major drug solubility, less in vivo and in vitro aggregation, less immunogenicity 
and allergenicity, minor degradation and opsonisation and minor kidney clearance [11–14]. The 
overall effect is an improvement in the drug pharmacokinetics, with an increasing of its life time 
and a reduction of the necessary dosage frequency for patients. Moreover the PEGylation of 
surfaces reduces the adsorption of other proteins that occurs in a physiological media, thanks to the 
high hydration of the hydrophilic polyether backbone and to an increased steric repulsion on the 
surface [15].  These shielding features are indicated as stealth effect of PEG.
Beyond the pharmacologic evaluation, the thermodynamic and structural protein stability  and 
its residual activity after the bioconjugation process [16–19] are fundamental issues that have to be 
explored in the development of any new pharmaceutical protein, in order to understand its 
potentialities. 
However, in our knowledge, just few studies regarding the thermodynamic stability of protein-
polymer conjugates appear in the literature [20–23] and despite some hypothesis have been 
advanced [23,24], the molecular mechanism by which PEGylation changes the protein 
thermodynamic stability and its behaviour in solution remains uncertain and the effects have to be 
evaluated case by case.
In the present work, myoglobin of equine skeletal muscle, a single chain protein containing 153 
amino acid residues, was selected for the synthesis of myoglobin-poly(ethylene glycol) conjugates.  
Such systems were studied by using differential scanning calorimetry and UV-visible spectroscopy 
in order to discriminate the thermodynamic contributions due to PEGylation on the overall protein 
stability, also focusing on the PEG’s role on the solvent-protein surface interaction that dictate 
denaturation reversibility and/or aggregation phenomena. Despite the simple primary and tertiary 
structure (with 19 lysinic residues available for bioconjugation), this protein shows low thermal 
reversibility [25] and high tendency to aggregate after the thermal denaturation and represents a 
sensitive model with respect to  the properties that we propose to investigate. 
2. Experimental section
2.1. Materials
Myoglobin of equine skeletal muscle was purchased from Sigma Aldrich, whereas Dulbecco's 
phosphate buffered saline without calcium and magnesium (DPBS) was purchased from Gibco/Life 
Technologies (Germany) and used as received. Borate buffer 50 mM was prepared making a 
solution of sodium tetraborate 50 mM (distilled water and Na2B4O7·10H2O, Sigma Aldrich 
Germany); the pH was adjusted with HCl 0.1 M until to be pH = 8.8. Poly(ethylene glycol) 
monomethyl ether (PEG) (Mn= 5 kDa) was purchased from Fluka and post-modified following the 
procedure reported by Zalipski [26], obtaining N-hydroxysuccinimide-poly(ethylene glycol) (PEG-
NHS). Sephadex G-50 medium (Sigma Aldrich) was allowed to swallow in water overnight before 
use, following the proportion Sephadex/water= 10mL/50mL; when the column was not in use, it 
was stored in a solution of 5% EtOH at 4°C.
The synthesis and characterization of the PEGylated samples My-PEG (1) and My-PEG (2) was 
performed following a procedure reported in detail in the literature for analogue conjugates [27]. 
Suffice here to say that for the two bioconjugates we obtained purity = 99 %, dispersity Đ = 1.051, 
number-average molar mass Mn = 47.490 and average number of attached chains = 3.3 for My-PEG 
(1), and purity = 97.5 %, dispersity Đ= 1.008, number-average molar mass Mn = 63.970 and average 
number of attached chains = 5.2 for My-PEG (2).
2.2. Differential Scanning Calorimetry (DSC) 
Calorimetric measurements were carried out in solution with a protein concentration of about 
1.5·10-4 M in DPBS at pH 7.0 with a Setaram Micro-DSCIII apparatus, equipped with 1 mL 
hermetically closed cylindrical pans, at 0.5°C·min-1 scan rate in the temperature range from 20°C to 
95°C. Some measurements were also performed by using the TA Instruments Nano-DSC (6300) 
equipped with capillary cells at the same scan rate. For all the experiments, a heating-cooling cycle 
was scheduled followed by a second heating scan. Data were analyzed by means of the software 
THESEUS [28] following procedures reported in previous studies [29]. Here it is sufficient to say 
that the excess molar heat capacity CPexc(T), i.e. the difference between the apparent molar heat 
capacity CP(T) of the sample and the molar heat capacity of the "native state", CP,N(T), was recorded 
across the scanned temperature range. The heat capacity drop, ΔdCP, across the signal was affected 
by a rather large error and was therefore not taken into account in the present work. The area 
underlying the recorded peaks, so treated, directly corresponds to the relevant denaturation 
enthalpy, ΔdH°, in kJmol−1 units. Errors were evaluated on the basis of at least three replicas. The 
fit attempts based on the denaturation thermodynamic models were accomplished using the 
nonlinear Levenberg–Marquardt method [30]. The errors of each fitting parameter were calculated 
with a 95.4% confidence limit by the Monte Carlo simulation method. 
2.3. UV-Vis measurements
The UV-Vis absorbance spectra of the samples’ solutions in DPBS were registered with a Jasco 
V-550 UV/VIS spectrometer in the range 200-600 nm. The initial protein concentration in the 
samples was between 1 and 1.5 mg/ml. The spectra were therefore normalized to the same protein 
concentration (1 mg/mL), using the intensity value recorded at 280 nm.
3. Results and discussion
3.1. Influence of bioconjugation on the reversibility of the protein thermal denaturation
Fig. 1: Myoglobin thermal denaturation.
Thermograms for unmodified myoglobin (1.5 ·10-4M in DPBS, pH 7.0, 0.5°C·min-1 scan rate) obtained by 
using both a micro-DSC with cylindrical cell (blue curve) and a nano-DSC with capillary cells (red curve). 
The blue curve was smoothed in order to reduce the noise due to aggregation effects. 
The blue curve in Fig. 1 reports the micro-DSC thermogram (with cylindrical cells) of the 
unmodified myoglobin. We observed a complex signal, namely an endothermic peak followed by a 
strong exothermic contribute ending with a noisy trace. This is a typical picture of overlapping 
processes, i.e. thermal denaturation of the protein with concomitant aggregation effect as expected 
for the myoglobin at this pH in line with the literature [31].
For sake of clarity and in an attempt to obtain information of the thermal stability of the protein in 
these conditions, despite the aggregation phenomena we also used a capillary cell DSC calorimeter 
and the resulting trace is reported in the same figure (red curve) showing a single endothermic peak. 
Indeed, the use of capillary cells seemed to mitigate the aggregation and/or precipitation 
phenomena. However, in both cases, the denaturation process resulted irreversible as revealed by 
the second heating scan (flat traces not reported). 
These results were in agreement with the information obtained by the spectroscopic analysis (UV 
absorbance, 280 nm; extinction coefficient: 1.66 mg·cm-1, [32]). Indeed, the occurrence of a 
thermal-induced aggregation of myoglobin was confirmed by the determination of the protein 
concentration in solution before and after the thermal scan, which showed a consistent decrease in 
protein concentration after the calorimetric run (reduction of 45%) besides the formation of a visible 
red precipitate.
Fig. 2: PEGylation effect on the bioconjugates thermal stability. 
Micro-DSC thermograms for My-PEG (1) and My-PEG (2) solutions (1.5 ·10-4M in DPBS, pH 7.0, 
0.5°C·min-1 scan rate) in panel a and b, respectively. First heating scans from 20 to 95°C (blue curves); 
cooling scans from 95 to 20°C (purple curves); second heating scans from 20 to 95°C (red curves).
Fig. 2 reports the micro-DSC traces obtained through a heating/cooling cycle followed by a 
second heating scan for the My-PEG (1) and My-PEG (2) proteins (panel a and b, respectively). In 
both cases we observed a single endothermic peak corresponding to the protein thermal 
denaturation with no evident exothermic phenomena. However, the following cooling (purple 
curves) and the second heating (red curves) scans indicated only a partial reversibility of the process 
(lower signals).  
Nevertheless, despite the partial reversibility in these experimental conditions (heating up to 
95°C), such a situation may correspond to a fully reversible process in the denaturation range, 
according to the literature [33]. In order to validate this hypothesis, a shorter heating/cooling cycle 
(up to 80°C) was performed for My-PEG (1) samples, followed by a complete second heating scan 
(Fig. 3). We observed that the first and the second heating scans were fully overlapped (blue and 
red curves, respectively) confirming that the bioconjugation enhance the thermal denaturation 
reversibility of the protein with respect the reference.  Moreover, the complete overlap between the 
second heating scan (red curve) and the first heating scan of the Fig.2a (reported in Fig. 3 as a grey 
trace) once again demonstrates our hypothesis and also verifies the reliability of the measurements. 
Again, these results were in agreement with the UV absorbance data. Indeed, the protein 
concentration in solution for the My-PEG (1) and My-PEG (2) samples was not significantly 
affected by the thermal scan. 
Fig. 3: Assessment of the My-PEG denaturation reversibility. 
Micro-DSC thermograms for My-PEG (1) solutions (1.5 ·10-4M in DPBS, pH 7.0, 0.5°C·min-1 scan rate). 
First heating scan from 20 to 80°C (blue curve); second heating scan from 20 to 95°C (red curve). The first 
heating scan from 20 to 95°C (grey curve, which corresponds to the blue curve in Fig.2a) is also reported to 
highlight the reliability of the measurements. 
Additional information on the bioconjugates in solution was provided by the UV-Vis 
absorption spectra of the samples in the wavelength range of 200-600 nm at room temperature. The 
absorbance spectra of My (black curve), My-PEG (1) (red curve) and My-PEG (2) (blue curve) are 
reported in Fig. 4 and indicate that the bioconjugation did not significantly affect the structure of the 
protein at room temperature. In particular, the profiles of all the samples presented a lower peak 
with the maximum at 280 nm and a more intense peak with the maximum at 409 nm. This second 
peak, called Soret band [34], is due to the absorbance of heme group and it is exquisitely sensitive 
to changes in local environment [35]. The comparison between the spectra of myoglobin, My-PEG 
(1) and My-PEG (2) recorded at room temperature showed only slight differences in the Soret band 
intensity with respect the reference. These slight differences, that regards a local effect on the heme 
group, were the same in the two conjugates and seemed not to compromise the functionality of the 
protein at room temperature according to previous results of activity assays that showed a high 
preservation of the protein activity [27].
Fig. 4: Proteins spectroscopic characterization.
UV-Vis absorption spectra of the samples My (black curve), My-PEG (1) (red curve) and My-PEG (2) (blue 
curve), normalized per protein concentration.
3.2. Thermodynamic analysis
The overall picture of My, My-PEG (1) and My-PEG (2) thermal unfolding is reported in Fig.5. 
Fig. 5: Thermodynamic modelling of the DSC profiles.
Thermograms from the first heating scan for My (capillary cells calorimeter), My-PEG (1), My-PEG (2) 
(circles curves from the right to the left, respectively) (1.5 ·10-4M in DPBS, pH 7.0, 0.5°C·min-1 scan rate). 
The blue, green and red traces are the respective theoretical curves calculated according to a single step 
denaturation model.  
It is evident that the bioconjugation has a destabilizing effect on this protein as regards both the 
denaturation enthalpy and temperature that are significantly decreased (see Table 1). 
The reversibility results of the PEGylated conjugates clearly indicate that a thermodynamic analysis 
of the denaturation mechanism is allowed [33]. Accordingly, thermodynamic models [36,37] were 
applied in order to describe the thermal denaturation of the PEGylated conjugates. A single step 
model native-to-denatured state was sufficient to obtain a good fit for the two protein-polymer 
conjugates. A tentative fit was also attempted on the unmodified myoglobin’s trace obtained by the 
capillary calorimeter. None thermodynamic model produced a satisfactory fit confirming that, in 
this case, the capillary cell was not totally able to avoid aggregation phenomena. However, although 
the denaturation and the aggregation processes may be concomitant, we may assume that the 
beginning of the peak is not strongly affected by the exothermic contribute. Therefore, for the sake 
of completeness and being aware of the possible miscalculation in the case of the unmodified 
protein, an attempt of a single step fit of the early part of the thermogram is also reported in Fig. 5, 
according to the one-state denaturation fitting model.  The best fit parameters obtained by these 
fitting attempts are also reported in Table 1.
Table 1: Denaturation enthalpy, ∆dH°, and temperature, Td, obtained by experimental DSC traces and best-
fit values for My, My-PEG (1) and My-PEG (2) samples. The fit parameters were calculated according to a 
one state denaturation model.
Experimental One state denaturation model Best-Fit parametersSystem
∆dH° / kJ∙mol-1 Td / °C ∆dH° / kJ∙mol-1 Td / °C
Myoglobin - - 540 80.7
My–PEG (1) 480 ± 25 76.7 ± 0.5 485 76.7
My–PEG (2) 415 ± 25 73.1 ± 0.5 410 73.1
We may conclude that the destabilizing effect of the bioconjugation on this protein seems to follow 
the extent of the covalent modification, but do not alter the mechanism of thermal denaturation that 
remains a single step mechanism. Furthermore, taking into account the unaltered functionality of 
the proteins at room temperature [27], we may argue that the reduced thermodynamic stability of 
bioconjugated myoglobin, is mainly due to the altered solvent-surface interactions that maybe affect 
more the denatured state of the protein, that seems do not reach a complete random coil state 
because of the boundaries dictated by the bioconjugation, rather than to peculiar reorganizations of 
the native protein tertiary structure, that remains functional at room temperature. This scenario is 
further supported by the reversibility enhancement in the case of both bioconjugate systems.
Formally, the  protein functionality and thermodynamic stability is dictated by the ΔdG°(T) = 
GD°(T) - GN°(T) equation [28], i.e. by the difference of the standard Gibbs energy between the 
denatured and the native state. Accordingly, the unaltered functionality of the proteins, at room 
temperature, suggests that this difference, i.e. the ΔdG°(25°C), should be remain the same for the 
three systems. Unfortunately, the DSC measurements of the proteins investigated in our conditions 
(see the experimental section) did not permit to directly measure the heat capacity drop, ΔdCP, for 
the tree systems, which represents an index of the solvent-exposed surface differences upon the 
denaturation [38–40] and in turn permits the ΔdG°(25°C) direct evaluation [28].
However, the calorimetric data (ΔdH°, Td) reported in Table 1 allowed to attempt a thermodynamic 
visualization of this scenario in relative terms, i.e. assuming, as reference, an arbitrary value for the 
ΔdCP of the unmodified protein in the range of those reported in the literature [38–40] in order to 
evaluate the corresponding ΔdG°(T). In this way, the ΔdCP, values for the PEGylated systems were 
estimated coherently, i.e. tentatively imposing the same ΔdG°(25°C) obtained for the unmodified 
myoglobin also for the two bioconjugates. The results of this attempt are shown in Fig. 6. Of 
course, the absolute ΔdCP values estimated for My-PEG (1) and My-PEG (2) depend on the ΔdCP 
value of the unmodified protein, here arbitrarily chosen, but in any case and in relative terms, this 
scenario predicts a severe reduction of ΔdCP for the PEGylated systems that follows the 
bioconjugation extent (Table 2), in line with all the experimental evidences in this work. 
Fig. 6: Estimation of the standard Gibbs energy trends.
Calculated ΔdG°(T) for My (blue curve), My-PEG (1) (green curve) and My-PEG (2) (red curve) according 
to the data reported in Table 1 and Table 2. The denaturation temperatures of My, My-PEG (1) and My-
PEG (2) are respectively indicated as Td,0, Td,1 and Td,2.
Table 2: Heat capacity drops and their relative reduction for My-PEG (1) and My-PEG (2) estimated by 
assuming the same ΔdG°(25°C) for all the systems and a nominal ∆dCp for My as reference.
System ∆dCp / kJ∙mol
-1∙K-
1
Relative 
reduction
Myoglobin  7.5a   -
My–PEG (1) 5.4 ~30%
My–PEG (2) 1.9 ~75%
a reference value assumed according to the literature.
4. Conclusions
The overall results of this study indicate that the bioconjugation process provides a thermal 
destabilization of myoglobin. However, such a modification does not alter the denaturation 
mechanism, which remains as one-step process, and does not substantially compromise the protein 
native structure as well as its functionality. Moreover, the use of poly(ethylene glycol) as stealth 
agent confers an enhanced reversibility to the denaturation process. The thermodynamic 
interpretation of the data indicated that the bioconjugation influences the solvent-exposed protein 
surface difference between native and denatured state. This variation seemed to follow the extent of 
the bioconjugation and is coherent with the prevention of aggregation phenomena and the 
consequent observed reversibility.
The calorimetric approach provides relevant complementary information for the overall 
characterization of new classes of protein-polymer conjugates as a base for the rational design of 
new drugs and for a deeper understanding of the behaviour of the samples in solution.
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Figure captions
Fig. 2: Myoglobin thermal denaturation.
Thermograms for unmodified myoglobin (1.5 ·10-4M in DPBS, pH 7.0, 0.5°C·min-1 scan rate) 
obtained by using both a micro-DSC with cylindrical cell (blue curve) and a nano-DSC with 
capillary cells (red curve). The blue curve was smoothed in order to reduce the noise due to 
aggregation effects.
Fig. 2: PEGylation effect on the bioconjugates thermal stability. 
Micro-DSC thermograms for My-PEG (1) and My-PEG (2) solutions (1.5 ·10-4M in DPBS, pH 7.0, 
0.5°C·min-1 scan rate) in panel a and b, respectively. First heating scans from 20 to 95°C (blue 
curves); cooling scans from 95 to 20°C (purple curves); second heating scans from 20 to 95°C (red 
curves).
Fig. 3: Assessment of the My-PEG denaturation reversibility. 
Micro-DSC thermograms for My-PEG (1) solutions (1.5 ·10-4M in DPBS, pH 7.0, 0.5°C·min-1 scan 
rate). First heating scan from 20 to 80°C (blue curve); second heating scan from 20 to 95°C (red 
curve). The first heating scan from 20 to 95°C (grey curve, which corresponds to the blue curve in 
Fig.2a) is also reported to highlight the reliability of the measurements.
Fig. 4: Proteins spectroscopic characterization.
UV-Vis absorption spectra of the samples My (black curve), My-PEG (1) (red curve) and My-PEG 
(2) (blue curve), normalized per protein concentration.
Fig. 5: Thermodynamic modelling of the DSC profiles.
Thermograms from the first heating scan for My (capillary cells calorimeter), My-PEG (1), My-
PEG (2) (circles curves from the right to the left, respectively) (1.5 ·10-4M in DPBS, pH 7.0, 
0.5°C·min-1 scan rate). The blue, green and red traces are the respective theoretical curves 
calculated according to a single step denaturation model.
Fig. 6: Estimation of the standard Gibbs energy trends.
Calculated ΔdG°(T) for My (blue curve), My-PEG (1) (green curve) and My-PEG (2) (red curve) 
according to the data reported in Table 1 and Table 2. The denaturation temperatures of My, My-
PEG (1) and My-PEG (2) are respectively indicated as Td,0, Td,1 and Td,2.
